10 September 2016

Weizmann’s Professor Ido Amit visits Garvan

It was the first time for Weizmann’s Professor Ido Amit to visit the Garvan Institute of Medical Research in Sydney, where he met senior staff to discuss the recently announced Garvan-Weizmann partnership to establish a centre for cellular genomics, currently under construction.

The strategic partnership will involve a staff and student exchange, the use of immunogentics to understand the immunological responses in complex diseases and the potential for clinical genome sequences supported by Weizmann’s prolific clinical databases.

In a presentation to Garvan staff entitled The power of one: Immunology in the age of single-cell genomics Professor Amit said the medical research potential of cellular genomics is enormous and will impact future development of immunotherapy drugs.

“This entails the measurement of the activity of the genome in thousands of individual cells which can reveal a huge amount of information, such as understanding changes that are likely to precede Alzheimer and cancer,” he said.

“We will also be able to see changes in cells that infiltrate a cancer or changes in brain cells that precede dementia. The potential is endless as cellular genomics can highlight entirely new opportunities for clinical intervention.

“This partnership will bring the expertise of two great institutes together to open up new doorways in our understanding and application of cellular genomics,” said Professor Amit.

Whilst at Garvan, Professor Amit toured Level 11 of The Kinghorn Cancer Centre – the site of the forthcoming Garvan-Weizmann Centre – with Garvan’s Deputy Director Professor Christopher Goodnow.

“It’s a great space and I can now visualise how it’s all going to look, it’s very exciting and I look forward to seeing the final result,” said Professor Amit.

Professor Goodnow said Professor Amit’s visit provided an ideal opportunity to determine how the research strengths of the two institutes can create synergies.

“In particular, we welcome the Weizmann Institute’s strengths in single-cell genomics and other key emerging technologies – and we look forward to sharing Garvan’s expertise in single cell analysis in cancer and diseases of immunity, bone, brain and metabolism, and in cancer genomics, epigenetics and whole genome sequencing.”

Garvan’s Executive Director, Professor John Mattick AO concluded: “The partnership between Garvan and Weizmann is a major development that brings two outstanding research institutes together to address major problems in understanding human biology and disease, and is another example of the global reach of both.”

  • Garvan’s Deputy Director Professor Christopher Goodnow with Weizmann's Professor Ido Amit (Photo thanks to Garvan Institute of Medical Research)

  • The Garvan-Weizmann space with artist's impression (Photo thanks to Garvan Institute of Medical Research)

  • Garvan’s Deputy Director Prof Christopher Goodnow and Weizmann's Prof Ido Amit check the plans for the new Garvan-Weizmann centre for cellular genomics (Photo thanks to the Garvan Institute of Medical Research)

Recent blog posts

view all +

8 October 2019 | Weizmann in Israel

Ebola Antibodies at work – a major vaccine study

A Weizmann Institute of Science laboratory has joined forces with a research team in Cologne, Germany, to uncover details of the immune system’s molecular response following vaccination against Ebola. Their...

read more +

17 September 2019 | Garvan-Weizmann Partnership

Weizmann VIPs visit Australia for Anniversary Celebrations

To celebrate the second anniversary of the Garvan-Weizmann Partnership, the Weizmann Institute of Science’s Vice President Elect, Professor Reich Ziv, and Head of Weizmann’s Crown Institute for Genomics, Dr Keren-ShaulHadas, came...

read more +

16 September 2019 | Weizmann in Israel

Cancer Protocols: A New Approach to Predicting Treatment Outcomes

New Weizmann Institute of Science research shows heterogeneity in melanoma tumours prevents effective immune responses. Diversity – at least among cancer cells – is not a good thing. Weizmann research...

read more +